Drug Index


Mechanism :

Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding- protein (PBP) targets.

Indication :

  • Wide spectrum antibiotic used to treat both Gram-positive and Gram-negative infections including pseudomonas spp. resistant to other antibiotics. Use to treat infections like meningitis, pneumonia and intra-abdominal infections, complicated skin/skin structure infections.

Contraindications :

Contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to b-lactams.

Dosing :

<32 weeks of gestation and <14 days of life:
20 mg/kg IV every 12 hours.
<32 weeks of gestation and >14 days of life or >32 weeks of gestation and <14 days of life:
20 mg/kg IV every 8 hours.
>32 weeks of gestation and >14 days of life: 20 mg/kg IV every 8 hours.
Double the dose in meningitis and severe infection.
Urinary tract Infection, soft tissue infection and skin infections:
10 mg/kg/dose IV every 8 hours. Max: 500 mg/dose.
Pneumonia, peritonitis, neutropenia, septicemia:
20 mg/kg/dose every 8 hours. Max: 1 gm/dose.
Meningitis and life threatening infections:
40 mg/kg IV every 8 hours. Max: 2 gm/dose.

Adverse Effect :

Commonly seen adverse reactions are constipation, local irritation at injection site, rashes, diarrhea, pseudo-membranous colitis (rarely), reversible neutropenia, apnoea, glossitis, pruritus, thrombocytopenia, eosinophilia, and thrombocythemia. Elevated LFTs may occur, Adverse CNS effects such as seizures have been reported.

Interaction :

Probenecid: Competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem.
Valproic acid: There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50500 mg – 2 g every 12 hours
10-20500 mg – 1 g every 12 hours or 500 mg every 8 hours
<10500 mg – 1 g every 24 hours

Dose in Patients undergoing Renal Replacement Therapies
CAPDDialysed. Dose as in GFR<10 mL/ min
HDDialysed. Dose as in GFR<10 mL/ min or 1–2 g post dialysis
HDF/High fluxDialysed. Dose as in GFR<10 mL/ min
CAV/VVHDDialysed. 0.5–1 g every 8 hours or 1 g every 12 hours
CVVHDF1 g every 12 hours

Hepatic Dose :

No dose adjustments are recommended.
03/23/2024 04:04:42 Meropenem
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0